Study of Blood and Tissue Samples to Understand Treatment Resistance in Prostate and Bladder Cancer

What this Trial Is About

Researchers are studying tissue and blood samples from patients with prostate or bladderurothelial cancer that has returned near the original tumor site or spread to other body parts. The study aims to better understand new biomarkers, possible drug targets, and how resistance to treatment develops. This research may help find improved ways to treat these cancers. Participants provide blood and tissue samples which are analyzed using mutation mapping, DNA sequencing, gene expression microarrays, and gene profiling. This observational study involves correlative laboratory biomarker analyses and cytology specimen collection procedures. The samples are collected from tumors, metastatic sites, or normal tissue when obtained during routine care or other research procedures. During the study, participants samples are evaluated for DNA sequencing, gene expression profiles, and mutation mapping for up to six years. Additional analyses include enzyme expression and proteomic profiling. The study involves periodic collection and testing of samples to explore molecular changes related to cancer sensitivity and resistance, with no direct treatment administered. Participants are monitored through these laboratory assessments throughout the study duration.

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer